Marksans Pharma Q4FY26: Record profitability, Australia inflection, and a bigger pipeline for the next leg

Marksans Pharma ended FY26 with its strongest reported year so far, combining steady top-line growth with improving profitability and a large net cash buffer. Consolidated total income for FY26 rose to INR 3,033.5 crore, while EBITDA reached INR 600.8 crore, translating into a 20.4% margin. Profit after tax stood at INR 420.1 crore.

Q4FY26 stood out as a high-profitability quarter. Total income came in at INR 891.3 crore and EBITDA at INR 195.4 crore, with the EBITDA margin rising to 22.8%. PAT for the quarter was INR 149.0 crore. Management attributed the quarter’s performance to operating leverage, a strong launch cadence, and higher other income, even as it flagged near-term raw material inflation pressures linked to geopolitical disruptions.

FY26 in numbers: growth supported by launches and mix

Marksans described FY26 as a year driven by new product introductions and stronger execution in its largest regulated markets. FY26 operating revenue was INR 2,950.9 crore, up 12.5% year on year, while total income including other income reached INR 3,033.5 crore.

The company’s business remains heavily anchored in consumer healthcare and store-brand OTC, with the presentation stating a FY26 mix of 80% OTC and 20% Rx. Within OTC, Marksans highlighted an approximate split of 85% store brands and 15% own labels, reinforcing its positioning as a preferred private-label partner in large developed markets.

A key feature of the FY26 narrative was the role of product launches. In the US and North America, the company launched 112 new SKUs during the year and reported 51 products in the pipeline. In the UK, it reported 18 product approvals and 30 filings in FY26, with 24 products awaiting approval as of 31 March 2026, and an intent to file over 200 products over the next four years.

Geography: US stays dominant, UK rebounds in Q4, Australia delivers a step-up

The revenue mix continued to be led by the US and North America, which delivered INR 1,533 crore in FY26 and grew 24% year on year. This region accounted for about 52% of operating revenue and remains the core engine for Marksans’ store-brand OTC scale-up. Q4FY26 revenue in the region was INR 406 crore, up 23.6% year on year. The company also noted that the slight sequential decline in Q4 versus Q3 was timing-related, linked to dispatch scheduling rather than demand.

UK and Europe remained the second-largest region, generating INR 1,015 crore in FY26, marginally down 1.4% year on year. The company attributed the softer full-year trend to a seasonally weak first quarter and high single-digit price erosion in select UK products earlier in the year. That pressure eased later, and Q4FY26 delivered what management described as the highest-ever quarterly revenue for the region at INR 308 crore, up 12.3% year on year and 19.2% sequentially.

Australia and New Zealand delivered the sharpest quarterly momentum. FY26 revenue was INR 303 crore, up 19.9% year on year, but Q4FY26 revenue surged to INR 123 crore, up 61.3% year on year and more than doubling sequentially. Management pointed to new launches and the structurally strong winter demand cycle as key contributors. Importantly, the company also marked FY26 as the year it entered branded prescription generics in Australia via Nova Pharma and launched 11 Rx brands, positioning this as a longer-term growth driver beyond OTC seasonality.

RoW remained a small contributor and weakened further through the year. FY26 RoW revenue was INR 99 crore, down 4.1% year on year. Q4FY26 revenue fell to INR 19 crore, with the company citing geopolitical disruptions, logistics constraints, and elevated payment risks in parts of MENA and CIS.

Strategy and capacity: operating leverage, pipeline depth, and M&A optionality

Marksans’ stated strategy is to become a reliable consumer healthcare partner, with focus areas spanning store-brand OTC expansion, a sustained R&D and pipeline engine, capacity scale-up, and selective acquisitions.

Manufacturing and operating leverage are central to this plan. The presentation states total installed capacity of 26 billion units per annum across facilities, with a roadmap milestone to expand India capacity to 16 billion units per annum by FY27-28. On the call, management indicated capacity utilisation across facilities at around 50% to 55%, with the acquired Goa unit providing scalable headroom. This matters because the company is attempting to push a higher share of growth through owned manufacturing, which supports margin resilience when volumes rise.

The balance sheet provides another lever. Marksans closed FY26 with a cash balance of about INR 990 crore, while cash generated from operations was INR 458 crore and capex was INR 131 crore. Management stated that free cash flow in FY26 was INR 328 crore and described the major capex cycle as nearly complete.

That cash position is also tied to inorganic growth readiness. Management said it is in active dialogue with two acquisition targets, with one currently in due diligence, and expressed optimism that calendar 2027 could see M&A activity. The company has already incorporated front-end entities in Germany and Ireland, and entered Canada through Marksans (Canada) Inc. Management expects Canada approvals to start trickling in toward the latter part of FY27 and indicated Europe could start contributing within FY27, with second-half timing referenced.

Margin outlook: near-term pressure acknowledged, FY27 guidance remains steady

While FY26 margins were stable overall, the quarter-to-quarter picture showed some volatility. Q4FY26 gross margin declined to 54.4% versus 58.1% in Q3FY26. Management linked this to rising input costs amid geopolitical tensions.

On the earnings call, management said it is witnessing 20% to 30% price escalation in petroleum-linked raw materials and expects inflationary pressure in Q1FY27. It also noted that inventory cover is meaningful for Q1 and that foreign exchange movements can partially offset input inflation. On freight, management indicated costs are creeping up but suggested the impact is not as severe as prior disruptions, referencing roughly a 2% level.

Despite the near-term cost commentary, management maintained that FY27 EBITDA margins should remain broadly in the same range as FY26 and guided to 15% to 20% revenue growth for FY27. Separately, it reiterated a target of INR 4,000 crore revenue within the next two years.

Takeaways

Marksans’ FY26 performance was defined by delivery against stated objectives, visible pipeline execution, and improving profitability in Q4. The US remains the primary scale driver, the UK showed a strong Q4 recovery with signs of stabilising price erosion, and Australia delivered a step-change quarter while opening up a new Rx growth lane through Nova Pharma.

The next phase hinges on three measurable themes already laid out by management: sustaining a high launch cadence in the US and UK, converting the newly incorporated Europe and Canada initiatives into revenue, and deploying the INR 990 crore cash balance into disciplined acquisitions without diluting margin stability. The company’s FY27 guidance of 15% to 20% growth and steady EBITDA margins sets a clear baseline that investors can track against quarterly execution.